PRESS RELEASE

Q3 2025 — Press release

Q3 2025PDF · 22 pages592 KB
For immediate release
Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook
• 2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational
growth of 4.4%*
• 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80
• Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA
subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus
LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump
• Company increases full year estimated reported sales 5 guidance to $93.7B or 5.7% at the midpoint; reaffirms full year
adjusted EPS 4 guidance of $10.85 at the midpoint, absorbing higher tax costs
New Brunswick, N.J. (October 14, 2025) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025.
“Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our
portfolio and significant progress across our pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson &
Johnson. “With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery
and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will
continue to transform lives.”
Overall financial results
Q3
($ in Millions, except EPS) 	2025 	2024 	% Change
Reported Sales 	$23,993 	$22,471 	6.8%
Net Earnings 	$5,152 	$2,694 	91.2%
EPS (diluted) 	$2.12 	$1.11 	91.0%
Q3
Non-GAAP* ($ in Millions, except EPS) 	2025 	2024 	% Change
Operational Sales 1,2 	5.4%
Adjusted Operational Sales 1,3 	4.4%
Adjusted Net Earnings 1,4 	$6,801 	$5,876 	15.7%
Adjusted EPS (diluted)1,4 	$2.80 	$2.42 	15.7%
Free Cash Flow 6,7 	~$14,200 	$14,471
1 	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 	Excludes the impact of translational currency
3 	Excludes the net impact of acquisitions and divestitures and translational currency
4 	Excludes intangible amortization expense and special items
5 	Excludes COVID-19 Vaccine
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com

-- 1 of 22 --

6 	Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from
operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
7 	Third-quarter YTD 2025 is estimated as of October 14, 2025
Note: values may have been rounded
Regional sales results
Q3 	% Change
($ in Millions) 	2025 	2024 	Reported 	Operational 1,2 	Currency
Adjusted
Operational 1,3
U.S. 	$13,708 	$12,909 	6.2% 	6.2 	- 	4.4
International 	10,285 	9,562 	7.6 	4.4 	3.2 	4.4
Worldwide 	$23,993 	$22,471 	6.8% 	5.4 	1.4 	4.4
1 	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 	Excludes the impact of translational currency
3 	Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q3 	% Change
($ in Millions) 	2025 	2024 	Reported 	Operational 1,2 	Currency
Adjusted
Operational 1,3
Innovative Medicine 	$15,563 	$14,580 	6.8% 	5.3 	1.5 	3.7
MedTech 	8,430 	7,891 	6.8 	5.6 	1.2 	5.7
Worldwide 	$23,993 	$22,471 	6.8% 	5.4 	1.4 	4.4
1 	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 	Excludes the impact of translational currency
3 	Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Third-Quarter 2025 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 5.3%*, with net acquisitions and divestitures positively impacting growth
by 1.6% due to CAPLYTA. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in
Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset
by an approximate (1,070) basis points impact from STELARA in Immunology, as well as IMBRUVICA in Oncology.
MedTech
MedTech worldwide operational sales grew 5.6%*, with net acquisitions and divestitures negatively impacting growth by 0.1%.
Growth was primarily driven by electrophysiology products, Abiomed and Shockwave in Cardiovascular, wound closure products
in General Surgery, as well as Surgical Vision.

-- 2 of 22 --

Full-year 2025 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to
predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related
expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on
various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) 	October 2025 	July 2025
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point 3.5% – 4.0% / 3.8% 	3.2% – 3.7% / 3.5%
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
$93.0B – $93.4B / $93.2B
4.8% – 5.3% / 5.1%
$92.7B – $93.1B / $92.9B
4.5% – 5.0% / 4.8%
Estimated Reported Sales3,5
/ Mid-point
Change vs. Prior Year / Mid-point
$93.5B – $93.9B / $93.7B
5.4% – 5.9% / 5.7%
$93.2B – $93.6B / $93.4B
5.1% – 5.6% / 5.4%
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.63 – $10.73 / $10.68
6.5% – 7.5% / 7.0%
$10.63 – $10.73 / $10.68
6.5% – 7.5% / 7.0%
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.80 – $10.90 / $10.85
8.2% – 9.2% / 8.7%
$10.80 – $10.90 / $10.85
8.2% – 9.2% / 8.7%
1 	Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 	Non-GAAP financial measure; excludes the impact of translational currency
3 	Calculated using Euro Average Rate: Oct 2025 = $1.13 and July 2025 = $1.13 (Illustrative purposes only)
4 	Non-GAAP financial measure; excludes intangible amortization expense and special items
5 	Excludes COVID-19 Vaccine
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the
Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual
Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations
section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and
www.factsabouttalc.com.
Regulatory
U.S. FDA approves TREMFYA (guselkumab) for the treatment of
pediatric plaque psoriasis and active psoriatic arthritis, marking a first
and only approval for an IL-23 inhibitor1
Press Release
TREMFYA (guselkumab) achieves U.S. approval for subcutaneous
induction in adults with ulcerative colitis, now the first and only IL-23
inhibitor with a fully subcutaneous regimen
Press Release
Johnson & Johnson receives positive CHMP opinion of nipocalimab to
treat a broad population of antibody-positive patients living with
generalised myasthenia gravis (gMG)
Press Release
Johnson & Johnson files with U.S. FDA to include new evidence in
TREMFYA (guselkumab) label as the only IL-23 inhibitor to demonstrate
significant inhibition of joint structural damage in active psoriatic
arthritis
Press Release

-- 3 of 22 --

European Commission approves DARZALEX (daratumumab) as the first
licensed treatment for patients with high-risk smouldering multiple
myeloma
Press Release
European Commission approves IMBRUVICA (ibrutinib) as the first
targeted therapy for patients with previously untreated mantle cell
lymphoma who would be eligible for autologous stem cell transplant
Press Release
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to
revolutionize treatment paradigm for adults and adolescents with
plaque psoriasis
Press Release
Data Releases Johnson & Johnson to highlight breadth of its major depressive
disorder portfolio at 2025 ECNP Congress1 	Press Release
Icotrokinra data in ulcerative colitis show potential for a standout
combination of therapeutic benefit and a favorable safety profile in
once-daily pill1
Press Release
TREMFYA (guselkumab) is first and only IL-23 inhibitor to demonstrate
sustained clinical and endoscopic outcomes with a fully subcutaneous
regimen through 48 weeks in ulcerative colitis 1
Press Release
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity
of Vision and Comfort of ACUVUE OASYS MAX 1-Day for
ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses1
Press Release
Johnson & Johnson’s investigational seltorexant shows numerically
higher response in patients with depression with insomnia symptoms,
with fewer side effects compared to quetiapine XR
Press Release
TECVAYLI plus DARZALEX FASPRO treatment demonstrates 100
percent overall response rate in transplant-eligible patients newly
diagnosed with multiple myeloma
Press Release
Icotrokinra shows superiority to deucravacitinib in first reported head-
to-head trials reinforcing promise of novel targeted oral peptide for
treatment of plaque psoriasis
Press Release
Johnson & Johnson to showcase industry-leading neuropsychiatry
innovations at the 2025 Psych Congress Annual Meeting 	Press Release
Data published in The New England Journal of Medicine demonstrate
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) is re-
setting survival expectations in first-line EGFR-mutated lung cancer
Press Release
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) prevents
acquired resistance versus osimertinib in first-line EGFR-mutated non-
small cell lung cancer
Press Release
New real-world data elevating patient perspectives highlight the need
for scientific advancement in maternal fetal immunology at ISUOG
2025
Press Release
Johnson & Johnson Unveils Results from the VARIPURE Substudy of
SECURE, a Real-World Study on VARIPULSE Platform, at 2025
European Society of Cardiology (ESC) Congress
Press Release
New Data from the DanGer Shock Randomized Control Trial, Published
in The New England Journal of Medicine, Confirms the Long-Term
Survival Benefit of the Impella CP Heart Pump
Press Release
Johnson & Johnson showcases latest advancements in Alzheimer's
research at AAIC 2025 Press Release
Product Launch
U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to
transform how certain bladder cancers are treated Press Release
Johnson & Johnson Launches VIRTUGUIDE AI-Powered Patient-
Matched Lapidus System in U.S. to Reduce Complexity in Bunion
Surgery for Millions
Press Release

-- 4 of 22 --

Other
Johnson & Johnson Elects John Morikis, Retired Chairman, President
and Chief Executive Officer of The Sherwin-Williams Company, to its
Board of Directors
Press Release
1 	Subsequent to the quarter
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson &
Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations
section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full
spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the
net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted
earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense
and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read
together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-
GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly
results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of
non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including
adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and
a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at
quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial performance, product development, and market position and
business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or
changes to applicable laws and regulations; competition, including technological advances, new products and patents attained

-- 5 of 22 --

by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans;
the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or
government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws
and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and
sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of
these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K,
including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and
in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from
Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson &
Johnson does not undertake to update any forward-looking statement as a result of new information or future events or
developments.

-- 6 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 	2024 	Total 	Operations 	Currency 	2025 	2024 	Total 	Operations 	Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 	9,402	$ 	8,871 	6.0 % 	6.0 	- 	26,655	$ 	24,993 	6.7 % 	6.7 	-
International 	6,161 	5,709 	7.9 	4.3 	3.6 	17,983 	17,639 	1.9 	1.3 	0.6
15,563 	14,580 	6.8 	5.3 	1.5 	44,638 	42,632 	4.7 	4.5 	0.2
MedTech
U.S. 	4,306 	4,038 	6.6 	6.6 	- 	12,902 	12,105 	6.6 	6.6 	-
International 	4,124 	3,853 	7.0 	4.5 	2.5 	12,089 	11,564 	4.5 	3.9 	0.6
8,430 	7,891 	6.8 	5.6 	1.2 	24,991 	23,669 	5.6 	5.3 	0.3
U.S. 	13,708 	12,909 	6.2 	6.2 	- 	39,557 	37,098 	6.6 	6.6 	-
International 	10,285 	9,562 	7.6 	4.4 	3.2 	30,072 	29,203 	3.0 	2.3 	0.7
Worldwide 	23,993	$ 	22,471 	6.8 % 	5.4 	1.4 	69,629	$ 	66,301 	5.0 % 	4.7 	0.3
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER 	NINE MONTHS
Percent Change

-- 7 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 	2024 	Total 	Operations 	Currency 	2025 	2024 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	13,708	$ 	12,909 	6.2 % 	6.2 	- 	39,557	$ 	37,098 	6.6 % 	6.6 	-
Europe 	5,440 	4,914 	10.7 	4.4 	6.3 	15,937 	15,291 	4.2 	1.5 	2.7
Western Hemisphere excluding U.S. 	1,231 	1,173 	4.9 	7.3 	(2.4) 	3,604 	3,579 	0.7 	7.6 	(6.9)
Asia-Pacific, Africa 	3,614 	3,475 	4.0 	3.4 	0.6 	10,531 	10,333 	1.9 	1.8 	0.1
International 	10,285 	9,562 	7.6 	4.4 	3.2 	30,072 	29,203 	3.0 	2.3 	0.7
Worldwide 	23,993	$ 	22,471 	6.8 % 	5.4 	1.4 	69,629	$ 	66,301 	5.0 % 	4.7 	0.3
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER 	NINE MONTHS
Percent Change

-- 8 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	23,993	$ 	100.0 	22,471	$ 	100.0 	6.8
Cost of products sold 	7,303 	30.4 	6,963 	31.0 	4.9
Gross Profit 	16,690 	69.6 	15,508 	69.0 	7.6
Selling, marketing and administrative expenses 	5,922 	24.7 	5,478 	24.3 	8.1
Research and development expense 	3,672 	15.3 	4,952 	22.0 	(25.8)
Interest (income) expense, net 	18 	0.1 	(99) 	(0.4)
Other (income) expense, net 	(478) 	(2.0) 	1,798 	8.0
Restructuring 	63 	0.3 	41 	0.2
Earnings before provision for taxes on income 	7,493 	31.2 	3,338 	14.9 	124.5
Provision for taxes on income 	2,341 	9.7 	644 	2.9 	263.5
Net earnings 	5,152	$ 	21.5 	2,694	$ 	12.0 	91.2
Net earnings per share (Diluted) 	2.12	$ 	1.11	$ 	91.0
Average shares outstanding (Diluted) 	2,428.6 	2,427.9
Effective tax rate 	31.2 % 	19.3 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	8,436	$ 	35.2 	7,277	$ 	32.4 	15.9
Net earnings 	6,801	$ 	28.3 	5,876	$ 	26.1 	15.7
Net earnings per share (Diluted) 	2.80	$ 	2.42	$ 	15.7
Effective tax rate 	19.4 % 	19.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2025 	2024

-- 9 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	69,629	$ 	100.0 	66,301	$ 	100.0 	5.0
Cost of products sold 	22,288 	32.0 	20,343 	30.7 	9.6
Gross Profit 	47,341 	68.0 	45,958 	69.3 	3.0
Selling, marketing and administrative expenses 	16,923 	24.3 	16,416 	24.8 	3.1
Research and development expense 	10,413 	15.0 	11,934 	18.0 	(12.7)
In-process research and development impairments 	- 	- 	194 	0.3
Interest (income) expense, net 	(62) 	(0.1) 	(433) 	(0.7)
Other (income) expense, net 	(7,692) 	(11.1) 	4,855 	7.3
Restructuring 	144 	0.2 	192 	0.3
Earnings before provision for taxes on income 	27,615 	39.7 	12,800 	19.3 	115.7
Provision for taxes on income 	5,927 	8.6 	2,165 	3.3 	173.8
Net earnings 	21,688	$ 	31.1 	10,635	$ 	16.0 	103.9
Net earnings per share (Diluted) 	8.94	$ 	4.38	$ 	104.1
Average shares outstanding (Diluted) 	2,424.8 	2,429.5
Effective tax rate 	21.5 % 	16.9 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	24,635	$ 	35.4 	23,558	$ 	35.5 	4.6
Net earnings 	20,206	$ 	29.0 	19,296	$ 	29.1 	4.7
Net earnings per share (Diluted) 	8.33	$ 	7.94	$ 	4.9
Effective tax rate 	18.0 % 	18.1 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2025 	2024

-- 10 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2025 	2024 	2025 	2024
Net Earnings, after tax- as reported 	$5,152 	$2,694 	$21,688 	$10,635
Pre-tax Adjustments
Litigation related 	15 	2,388 	(6,894) 	5,466
Intangible Asset Amortization expense 	1,048 	1,171 	3,435 	3,355
COVID-19 Vaccine related costs 	- 	4 	- 	77
Restructuring related 1 	168 	47 	302 	207
Medical Device Regulation 	- 	38 	- 	157
Acquisition, integration and divestiture related 	97 	328 	475 	928
(Gains)/losses on securities 	(387) 	(37) 	(327) 	374
IPR&D impairments 	- 	- 	- 	194
Other 	2 	- 	29 	-
Tax Adjustments
Tax impact on special item adjustments 2 	(168) 	(762) 	826 	(2,055)
Tax legislation and other tax related 	874 	5 	672 	(42)
Adjusted Net Earnings, after tax 	$6,801 	$5,876 	$20,206 	$19,296
Average shares outstanding (Diluted) 	2,428.6 	2,427.9 	2,424.8 	2,429.5
Adjusted net earnings per share (Diluted) 	$2.80 	$2.42 	$8.33 	$7.94
Operational adjusted net earnings per share (Diluted) 	$2.72 	$8.24
Notes:
1
2
Third Quarter 	Nine Months Ended
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit
to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial
virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100 million Q3 2024 YTD) included the termination of partnered and
non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network
arrangements. The restructuring expense of $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) and $28 million in the fiscal third quarter of 2024 ($107 million Q3 2024 YTD) primarily
includes costs related to market and product exits.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select
sites across the network. The restructuring expense of $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to asset impairments and market and product exits.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 11 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	6.8% 	6.8% 	6.8%
U.S. 	6.0% 	6.6% 	6.2%
International 	7.9% 	7.0% 	7.6%
WW Currency 	1.5 	1.2 	1.4
U.S. 	- 	- 	-
International 	3.6 	2.5 	3.2
WW Operational 	5.3% 	5.6% 	5.4%
U.S. 	6.0% 	6.6% 	6.2%
International 	4.3% 	4.5% 	4.4%
Caplyta 	(1.6) 	(1.1)
U.S. 	(2.7) 	(1.9)
International 	0.0 	0.0
All Other Acquisitions and Divestitures (A&D) 	0.0 	0.1 	0.1
U.S. 	0.0 	0.2 	0.1
International 	0.0 	0.1 	0.0
WW Adjusted Operational Ex A&D 	3.7% 	5.7% 	4.4%
U.S. 	3.3% 	6.8% 	4.4%
International 	4.3% 	4.6% 	4.4%
Adjusted Operational Sales Growth
THIRD QUARTER 2025 ACTUAL vs. 2024 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	4.7% 	5.6% 	5.0%
U.S. 	6.7% 	6.6% 	6.6%
International 	1.9% 	4.5% 	3.0%
WW Currency 	0.2 	0.3 	0.3
U.S. 	- 	- 	-
International 	0.6 	0.6 	0.7
WW Operational 	4.5% 	5.3% 	4.7%
U.S. 	6.7% 	6.6% 	6.6%
International 	1.3% 	3.9% 	2.3%
Shockwave 	(1.9) 	(0.6)
U.S. 	(2.9) 	(0.9)
International 	(0.8) 	(0.2)
Caplyta 	(1.1) 	(0.7)
U.S. 	(1.8) 	(1.2)
International 	0.0 	0.0
All Other Acquisitions and Divestitures (A&D) 	0.0 	0.3 	0.1
U.S. 	0.0 	0.4 	0.1
International 	0.1 	0.2 	0.1
WW Adjusted Operational Ex A&D 	3.4% 	3.7% 	3.5%
U.S. 	4.9% 	4.1% 	4.6%
International 	1.4% 	3.3% 	2.2%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2025 ACTUAL vs. 2024 ACTUAL
Segments

-- 13 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2025 	2024 	Reported 	Operational (1) Currency 	2025 	2024 	Reported 	Operational (1) Currency
ONCOLOGY
US 	3,468	$ 	2,816 	23.2% 	23.2% 	- 	9,866	$ 	7,835 	25.9% 	25.9% 	-
Intl 	3,060 	2,565 	19.3% 	14.8% 	4.5% 	8,652 	7,450 	16.1% 	15.0% 	1.1%
WW 	6,529 	5,380 	21.3% 	19.2% 	2.1% 	18,519 	15,284 	21.2% 	20.6% 	0.6%
CARVYKTI
US 	396 	258 	53.3% 	53.3% 	- 	1,072 	565 	89.6% 	89.6% 	-
Intl 	128 	27 	* 	* 	* 	260 	63 	* 	* 	*
WW 	524 	286 	83.5% 	81.4% 	2.1% 	1,332 	629 	* 	* 	*
DARZALEX
US 	2,088 	1,684 	24.0% 	24.0% 	- 	5,934 	4,789 	23.9% 	23.9% 	-
Intl 	1,584 	1,332 	18.9% 	14.7% 	4.2% 	4,514 	3,797 	18.9% 	17.9% 	1.0%
WW 	3,672 	3,016 	21.7% 	19.9% 	1.8% 	10,448 	8,586 	21.7% 	21.3% 	0.4%
ERLEADA
US 	378 	337 	12.3% 	12.3% 	- 	1,048 	940 	11.5% 	11.5% 	-
Intl 	558 	453 	23.0% 	17.6% 	5.4% 	1,567 	1,275 	22.9% 	21.1% 	1.8%
WW 	936 	790 	18.4% 	15.3% 	3.1% 	2,615 	2,215 	18.0% 	17.0% 	1.0%
IMBRUVICA
US 	211 	259 	(18.3)% 	(18.3)% 	- 	685 	770 	(11.0)% 	(11.0)% 	-
Intl 	483 	494 	(2.3)% 	(6.6)% 	4.3% 	1,453 	1,537 	(5.4)% 	(6.4)% 	1.0%
WW 	695 	753 	(7.8)% 	(10.6)% 	2.8% 	2,139 	2,307 	(7.3)% 	(7.9)% 	0.6%
RYBREVANT / LAZCLUZE (3)
US 	136 	68 	99.7% 	99.7% 	- 	388 	156 	* 	* 	-
Intl 	61 	21 	* 	* 	* 	130 	49 	* 	* 	*
WW 	198 	89 	* 	* 	* 	518 	205 	* 	* 	*
TALVEY
US 	85 	64 	34.2% 	34.2% 	- 	235 	173 	35.8% 	35.8% 	-
Intl 	37 	12 	* 	* 	* 	79 	29 	* 	* 	*
WW 	122 	75 	60.8% 	59.1% 	1.7% 	314 	202 	55.3% 	54.9% 	0.4%
TECVAYLI
US 	115 	105 	9.3% 	9.3% 	- 	334 	310 	7.5% 	7.5% 	-
Intl 	62 	30 	* 	* 	* 	160 	93 	73.0% 	72.6% 	0.4%
WW 	177 	135 	31.3% 	29.9% 	1.4% 	494 	403 	22.6% 	22.5% 	0.1%
ZYTIGA / abiraterone acetate
US 	5 	5 	(25.0)% 	(25.0)% 	- 	18 	25 	(30.4)% 	(30.4)% 	-
Intl 	108 	144 	(25.1)% 	(26.8)% 	1.7% 	365 	470 	(22.3)% 	(23.0)% 	0.7%
WW 	113 	150 	(25.1)% 	(26.8)% 	1.7% 	383 	496 	(22.8)% 	(23.4)% 	0.6%
OTHER ONCOLOGY
US 	56 	36 	54.6% 	54.6% 	- 	153 	106 	44.8% 	44.8% 	-
Intl 	39 	50 	(22.2)% 	(25.6)% 	3.4% 	123 	136 	(9.7)% 	(10.6)% 	0.9%
WW 	94 	86 	9.7% 	7.7% 	2.0% 	276 	242 	14.0% 	13.6% 	0.4%
See footnotes at end of schedule
% Change 	% Change

-- 14 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2025 	2024 	Reported 	Operational (1) Currency 	2025 	2024 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,676	$ 	3,068 	(12.8)% 	(12.8)% 	- 	7,377	$ 	8,499 	(13.2)% 	(13.2)% 	-
Intl 	1,493 	1,552 	(3.9)% 	(6.3)% 	2.4% 	4,492 	5,090 	(11.8)% 	(11.5)% 	(0.3)%
WW 	4,168 	4,621 	(9.8)% 	(10.6)% 	0.8% 	11,868 	13,590 	(12.7)% 	(12.6)% 	(0.1)%
REMICADE
US 	326 	281 	16.2% 	16.2% 	- 	923 	778 	18.7% 	18.7% 	-
US Exports (4) 19 	27 	(30.9)% 	(30.9)% 	- 	63 	89 	(29.6)% 	(29.6)% 	-
Intl 	132 	112 	17.7% 	16.7% 	1.0% 	413 	380 	8.6% 	10.4% 	(1.8)%
WW 	476 	419 	13.6% 	13.3% 	0.3% 	1,398 	1,246 	12.2% 	12.7% 	(0.5)%
SIMPONI / SIMPONI ARIA
US 	309 	299 	3.6% 	3.6% 	- 	906 	820 	10.5% 	10.5% 	-
Intl 	377 	218 	73.0% 	69.8% 	3.2% 	1,130 	787 	43.5% 	44.6% 	(1.1)%
WW 	687 	516 	32.9% 	31.5% 	1.4% 	2,036 	1,607 	26.7% 	27.2% 	(0.5)%
STELARA
US 	1,022 	1,770 	(42.3)% 	(42.3)% 	- 	3,081 	5,021 	(38.6)% 	(38.6)% 	-
Intl 	549 	906 	(39.4)% 	(41.4)% 	2.0% 	1,768 	2,991 	(40.9)% 	(40.8)% 	(0.1)%
WW 	1,570 	2,676 	(41.3)% 	(42.0)% 	0.7% 	4,848 	8,012 	(39.5)% 	(39.5)% 	0.0%
TREMFYA
US 	989 	691 	43.1% 	43.1% 	- 	2,384 	1,789 	33.3% 	33.3% 	-
Intl 	434 	316 	37.4% 	33.4% 	4.0% 	1,181 	932 	26.7% 	26.1% 	0.6%
WW 	1,424 	1,007 	41.3% 	40.1% 	1.2% 	3,566 	2,721 	31.0% 	30.8% 	0.2%
OTHER IMMUNOLOGY
US 	12 	1 	* 	* 	- 	21 	3 	* 	* 	-
Intl 	0 	0 	- 	- 	- 	0 	0 	- 	- 	-
WW 	12 	1 	* 	* 	- 	21 	3 	* 	* 	-
NEUROSCIENCE
US 	1,367 	1,094 	25.0% 	25.0% 	- 	3,712 	3,250 	14.2% 	14.2% 	-
Intl 	658 	662 	(0.7)% 	(2.6)% 	1.9% 	2,011 	2,090 	(3.8)% 	(3.7)% 	(0.1)%
WW 	2,024 	1,755 	15.3% 	14.6% 	0.7% 	5,722 	5,340 	7.2% 	7.2% 	0.0%
CAPLYTA (5)
US 	240 	- 	* 	* 	- 	451 	- 	* 	* 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	240 	- 	* 	* 	- 	451 	- 	* 	* 	-
CONCERTA / Methylphenidate
US 	14 	26 	(49.2)% 	(49.2)% 	- 	76 	101 	(24.9)% 	(24.9)% 	-
Intl 	127 	117 	9.0% 	8.5% 	0.5% 	376 	382 	(1.4)% 	(0.4)% 	(1.0)%
WW 	140 	142 	(1.4)% 	(1.8)% 	0.4% 	452 	482 	(6.3)% 	(5.5)% 	(0.8)%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	664 	780 	(14.9)% 	(14.9)% 	- 	2,021 	2,329 	(13.2)% 	(13.2)% 	-
Intl 	267 	269 	(0.9)% 	(3.0)% 	2.1% 	804 	830 	(3.1)% 	(3.0)% 	(0.1)%
WW 	929 	1,049 	(11.3)% 	(11.9)% 	0.6% 	2,824 	3,159 	(10.6)% 	(10.5)% 	(0.1)%
SPRAVATO
US 	405 	243 	67.1% 	67.1% 	- 	1,047 	660 	58.7% 	58.7% 	-
Intl 	53 	42 	28.9% 	23.8% 	5.1% 	146 	120 	21.9% 	21.4% 	0.5%
WW 	459 	284 	61.5% 	60.8% 	0.7% 	1,193 	780 	53.0% 	52.9% 	0.1%
OTHER NEUROSCIENCE
US 	46 	46 	0.4% 	0.4% 	- 	119 	161 	(26.4)% 	(26.4)% 	-
Intl 	210 	235 	(10.7)% 	(12.3)% 	1.6% 	684 	759 	(9.8)% 	(9.9)% 	0.1%
WW 	256 	281 	(8.9)% 	(10.2)% 	1.3% 	803 	920 	(12.7)% 	(12.8)% 	0.1%
See footnotes at end of schedule
% Change 	% Change

-- 15 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2025 	2024 	Reported 	Operational (1) Currency 	2025 	2024 	Reported 	Operational (1) Currency
PULMONARY HYPERTENSION
US 	815	$ 	815 	(0.1)% 	(0.1)% 	- 	2,358	$ 	2,324 	1.5% 	1.5% 	-
Intl 	300 	287 	4.8% 	2.0% 	2.8% 	895 	866 	3.4% 	2.6% 	0.8%
WW 	1,115 	1,102 	1.1% 	0.4% 	0.7% 	3,253 	3,190 	2.0% 	1.8% 	0.2%
OPSUMIT / OPSYNVI
US 	409 	417 	(1.6)% 	(1.6)% 	- 	1,175 	1,149 	2.3% 	2.3% 	-
Intl 	168 	166 	1.1% 	(1.8)% 	2.9% 	507 	506 	0.2% 	(0.7)% 	0.9%
WW 	578 	583 	(0.8)% 	(1.7)% 	0.9% 	1,682 	1,655 	1.7% 	1.4% 	0.3%
UPTRAVI
US 	392 	379 	3.5% 	3.5% 	- 	1,139 	1,120 	1.7% 	1.7% 	-
Intl 	92 	80 	15.2% 	12.0% 	3.2% 	272 	232 	17.0% 	16.4% 	0.6%
WW 	484 	458 	5.6% 	5.0% 	0.6% 	1,411 	1,352 	4.3% 	4.2% 	0.1%
OTHER PULMONARY HYPERTENSION
US 	13 	21 	(36.5)% 	(36.5)% 	- 	44 	56 	(21.5)% 	(21.5)% 	-
Intl 	39 	39 	(1.0)% 	(2.5)% 	1.5% 	116 	127 	(8.9)% 	(9.1)% 	0.2%
WW 	53 	60 	(13.1)% 	(14.1)% 	1.0% 	160 	183 	(12.7)% 	(12.9)% 	0.2%
INFECTIOUS DISEASES
US 	326 	365 	(10.5)% 	(10.5)% 	- 	961 	1,023 	(6.0)% 	(6.0)% 	-
Intl 	501 	471 	6.4% 	0.5% 	5.9% 	1,472 	1,599 	(7.9)% 	(9.8)% 	1.9%
WW 	829 	836 	(0.9)% 	(4.3)% 	3.4% 	2,434 	2,622 	(7.2)% 	(8.3)% 	1.1%
EDURANT / rilpivirine
US 	7 	8 	(7.9)% 	(7.9)% 	- 	21 	24 	(11.8)% 	(11.8)% 	-
Intl 	378 	323 	16.9% 	9.9% 	7.0% 	1,082 	926 	16.8% 	13.6% 	3.2%
WW 	385 	330 	16.4% 	9.5% 	6.9% 	1,103 	950 	16.1% 	13.0% 	3.1%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	315 	355 	(11.0)% 	(11.0)% 	- 	932 	990 	(5.8)% 	(5.8)% 	-
Intl 	81 	94 	(13.6)% 	(18.5)% 	4.9% 	264 	315 	(16.1)% 	(16.6)% 	0.5%
WW 	397 	449 	(11.6)% 	(12.6)% 	1.0% 	1,196 	1,305 	(8.3)% 	(8.4)% 	0.1%
OTHER INFECTIOUS DISEASES
US 	4 	3 	57.3% 	57.3% 	- 	8 	10 	(11.0)% 	(11.0)% 	-
Intl 	42 	54 	(21.2)% 	(22.3)% 	1.1% 	126 	358 	(64.7)% 	(64.6)% 	(0.1)%
WW 	47 	56 	(17.5)% 	(18.5)% 	1.0% 	135 	367 	(63.3)% 	(63.2)% 	(0.1)%
CARDIOVASCULAR / METABOLISM / OTHER
US 	750 	713 	5.3% 	5.3% 	- 	2,381 	2,061 	15.5% 	15.5% 	-
Intl 	149 	170 	(13.1)% 	(15.6)% 	2.5% 	461 	543 	(15.2)% 	(14.7)% 	(0.5)%
WW 	899 	884 	1.7% 	1.2% 	0.5% 	2,842 	2,605 	9.1% 	9.2% 	(0.1)%
XARELTO
US 	635 	592 	7.4% 	7.4% 	- 	1,946 	1,697 	14.7% 	14.7% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	635 	592 	7.4% 	7.4% 	- 	1,946 	1,697 	14.7% 	14.7% 	-
OTHER
US 	115 	121 	(5.2)% 	(5.2)% 	- 	435 	364 	19.4% 	19.4% 	-
Intl 	149 	170 	(13.1)% 	(15.6)% 	2.5% 	461 	543 	(15.2)% 	(14.7)% 	(0.5)%
WW 	264 	292 	(9.8)% 	(11.3)% 	1.5% 	896 	908 	(1.3)% 	(1.0)% 	(0.3)%
TOTAL INNOVATIVE MEDICINE
US 	9,402 	8,871 	6.0% 	6.0% 	- 	26,655 	24,993 	6.7% 	6.7% 	-
Intl 	6,161 	5,709 	7.9% 	4.3% 	3.6% 	17,983 	17,639 	1.9% 	1.3% 	0.6%
WW 	15,563	$ 	14,580 	6.8% 	5.3% 	1.5% 	44,638	$ 	42,632 	4.7% 	4.5% 	0.2%
See footnotes at end of schedule
% Change 	% Change

-- 16 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
MEDTECH SEGMENT (2) 2025 	2024 	Reported 	Operational (1) Currency 	2025 	2024 	Reported 	Operational (1) Currency
CARDIOVASCULAR
US 	1,306	$ 	1,148 	13.8% 	13.8% 	- 	3,931	$ 	3,292 	19.4% 	19.4% 	-
Intl 	908 	819 	10.8% 	8.4% 	2.4% 	2,698 	2,353 	14.6% 	13.8% 	0.8%
WW 	2,213 	1,966 	12.6% 	11.6% 	1.0% 	6,629 	5,645 	17.4% 	17.1% 	0.3%
ELECTROPHYSIOLOGY
US 	720 	660 	9.1% 	9.1% 	- 	2,145 	2,057 	4.3% 	4.3% 	-
Intl 	698 	619 	12.6% 	10.4% 	2.2% 	2,064 	1,889 	9.2% 	8.6% 	0.6%
WW 	1,418 	1,279 	10.8% 	9.7% 	1.1% 	4,209 	3,946 	6.7% 	6.4% 	0.3%
ABIOMED
US 	336 	293 	14.5% 	14.5% 	- 	1,035 	905 	14.3% 	14.3% 	-
Intl 	86 	68 	26.8% 	20.2% 	6.6% 	256 	207 	23.9% 	20.7% 	3.2%
WW 	423 	362 	16.8% 	15.6% 	1.2% 	1,291 	1,112 	16.1% 	15.5% 	0.6%
SHOCKWAVE(6)
US 	220 	163 	34.4% 	34.4% 	- 	659 	240 	* 	* 	-
Intl 	59 	66 	(11.2)% 	(12.4)% 	1.2% 	169 	66 	* 	* 	*
WW 	278 	229 	21.2% 	20.9% 	0.3% 	828 	306 	* 	* 	*
OTHER CARDIOVASCULAR
US 	30 	30 	0.0% 	0.0% 	- 	93 	89 	4.2% 	4.2% 	-
Intl 	65 	66 	(1.0)% 	(2.5)% 	1.5% 	209 	192 	9.0% 	8.7% 	0.3%
WW 	95 	96 	(0.7)% 	(1.7)% 	1.0% 	302 	281 	7.5% 	7.2% 	0.3%
ORTHOPAEDICS
US 	1,396 	1,359 	2.7% 	2.7% 	- 	4,200 	4,229 	(0.7)% 	(0.7)% 	-
Intl 	878 	832 	5.6% 	1.9% 	3.7% 	2,620 	2,614 	0.3% 	(1.1)% 	1.4%
WW 	2,274 	2,191 	3.8% 	2.4% 	1.4% 	6,820 	6,843 	(0.3)% 	(0.8)% 	0.5%
HIPS
US 	262 	250 	4.7% 	4.7% 	- 	796 	785 	1.3% 	1.3% 	-
Intl 	144 	131 	9.7% 	5.9% 	3.8% 	440 	435 	1.2% 	0.0% 	1.2%
WW 	405 	381 	6.4% 	5.1% 	1.3% 	1,235 	1,220 	1.3% 	0.9% 	0.4%
KNEES
US 	216 	212 	2.1% 	2.1% 	- 	673 	684 	(1.5)% 	(1.5)% 	-
Intl 	160 	140 	14.3% 	10.9% 	3.4% 	482 	463 	4.0% 	3.0% 	1.0%
WW 	377 	352 	7.0% 	5.6% 	1.4% 	1,155 	1,147 	0.7% 	0.3% 	0.4%
TRAUMA
US 	512 	497 	3.0% 	3.0% 	- 	1,515 	1,499 	1.1% 	1.1% 	-
Intl 	281 	265 	6.4% 	2.5% 	3.9% 	818 	786 	4.1% 	2.7% 	1.4%
WW 	793 	761 	4.2% 	2.9% 	1.3% 	2,333 	2,285 	2.1% 	1.6% 	0.5%
SPINE, SPORTS & OTHER
US 	406 	400 	1.3% 	1.3% 	- 	1,216 	1,262 	(3.7)% 	(3.7)% 	-
Intl 	293 	296 	(1.1)% 	(4.8)% 	3.7% 	881 	930 	(5.3)% 	(6.8)% 	1.5%
WW 	698 	696 	0.3% 	(1.3)% 	1.6% 	2,096 	2,191 	(4.3)% 	(5.0)% 	0.7%
See footnotes at end of schedule
% Change 	% Change

-- 17 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2025 	2024 	Reported 	Operational (1) Currency 	2025 	2024 	Reported 	Operational (1) Currency
SURGERY
US 	1,031	$ 	983 	4.9% 	4.9% 	- 	3,076	$ 	2,965 	3.8% 	3.8% 	-
Intl 	1,511 	1,451 	4.1% 	2.2% 	1.9% 	4,417 	4,373 	1.0% 	0.9% 	0.1%
WW 	2,542 	2,434 	4.4% 	3.3% 	1.1% 	7,493 	7,338 	2.1% 	2.1% 	0.0%
ADVANCED
US 	477 	448 	6.2% 	6.2% 	- 	1,411 	1,360 	3.7% 	3.7% 	-
Intl 	688 	661 	4.2% 	2.1% 	2.1% 	1,991 	1,977 	0.7% 	0.5% 	0.2%
WW 	1,165 	1,109 	5.0% 	3.8% 	1.2% 	3,402 	3,337 	1.9% 	1.8% 	0.1%
GENERAL
US 	555 	535 	3.8% 	3.8% 	- 	1,666 	1,605 	3.8% 	3.8% 	-
Intl 	823 	791 	4.0% 	2.2% 	1.8% 	2,426 	2,397 	1.2% 	1.3% 	(0.1)%
WW 	1,378 	1,325 	3.9% 	2.9% 	1.0% 	4,092 	4,001 	2.3% 	2.3% 	0.0%
VISION
US 	571 	549 	4.2% 	4.2% 	- 	1,694 	1,619 	4.7% 	4.7% 	-
Intl 	828 	751 	10.2% 	7.5% 	2.7% 	2,354 	2,224 	5.8% 	5.0% 	0.8%
WW 	1,400 	1,300 	7.7% 	6.1% 	1.6% 	4,048 	3,843 	5.3% 	4.8% 	0.5%
CONTACT LENSES / OTHER
US 	456 	441 	3.5% 	3.5% 	- 	1,337 	1,288 	3.8% 	3.8% 	-
Intl 	562 	527 	6.6% 	3.4% 	3.2% 	1,565 	1,508 	3.8% 	2.4% 	1.4%
WW 	1,018 	968 	5.2% 	3.5% 	1.7% 	2,902 	2,796 	3.8% 	3.1% 	0.7%
SURGICAL
US 	116 	108 	7.0% 	7.0% 	- 	358 	331 	8.0% 	8.0% 	-
Intl 	266 	225 	18.7% 	17.1% 	1.6% 	789 	717 	10.1% 	10.3% 	(0.2)%
WW 	383 	333 	14.9% 	13.8% 	1.1% 	1,147 	1,048 	9.4% 	9.6% 	(0.2)%
TOTAL MEDTECH
US 	4,306 	4,038 	6.6% 	6.6% 	- 	12,902 	12,105 	6.6% 	6.6% 	-
Intl 	4,124 	3,853 	7.0% 	4.5% 	2.5% 	12,089 	11,564 	4.5% 	3.9% 	0.6%
WW 	8,430	$ 	7,891 	6.8% 	5.6% 	1.2% 	24,991	$ 	23,669 	5.6% 	5.3% 	0.3%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
(6) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International
revenue includes ~$20M of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount
was immaterial to recast prior year reporting.
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore,
may not recalculate precisely
% Change	% Change

-- 18 of 22 --

Innovative Medicine
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 	3,672	$ 	(568) 	(11) 	3,093
Selling, marketing and admin expenses 	2,869 	2,869
Research and development expense 	2,944 	2,944
Other segment items 	(368) 	5 	(48) 	174 	(1) 	(238)
Adjusted Income Before Tax by Segment 	6,446 	568 	(5) 	- 	59 	(174) 	- 	1 	6,895
MedTech
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 	3,612	$ 	(480) 	(12) 	(1) 	3,119
Selling, marketing and admin expenses 	2,801 	2,801
Research and development expense 	728 	728
Other segment items 	2 	5 	(156) 	(48) 	213 	(1) 	15
Adjusted Income Before Tax by Segment 	1,287 	480 	(5) 	168 	49 	(213) 	- 	1 	1,767
Expenses not allocated to segments
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 	19	$ 	19
Selling, marketing and admin expenses 	252 	252
Research and development expense 	- 	-
Other segment items 	(31) 	(25) 	11 	(45)
Adjusted Income Before Tax by Segment 	(240) 	- 	25 	- 	(11) 	- 	- 	- 	(226)
Johnson & Johnson Consolidated
Third Quarter
Sept 28, 2025
GAAP
Intangible
asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 	7,303	$ 	(1,048) 	(12) 	(12) 	6,231
Selling, marketing and admin expenses 	5,922 	5,922
Research and development expense 	3,672 	3,672
Other (Income) / Expense 	(478) 	(15) 	(93) 	(85) 	387 	(2) 	(286)
In-process research and development impairments 	- 	-
Interest (Income)/Expense 	18 	18
Restructuring 	63 	(63) 	-
Adjusted Income Before Tax 	7,493 	1,048 	15 	168 	97 	(387) 	- 	2 	8,436
Provision for taxes on income 	2,341 	193 	3 	34 	16 	(87) 	(874) 	9 	1,635
Net Earnings 	5,152 	855 	12 	134 	81 	(300) 	874 	(7) 	6,801
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 19 of 22 --

Innovative Medicine
Third Quarter
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Third Quarter
Sept 29, 2024
Non-GAAP
Cost of products sold 	3,549	$ 	(695) 	(2) 	2,852
Selling, marketing and admin expenses 	2,491 	2,491
Research and development expense 	4,213 	(2) 	4,211
Other segment items 	(155) 	(356) 	(19) 	(6) 	41 	(495)
Adjusted Income Before Tax by Segment 	4,482 	695 	356 	19 	6 	(41) 	- 	4 	- 	5,521
MedTech
Third Quarter
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Third Quarter
Sept 29, 2024
Non-GAAP
Cost of products sold 	3,381	$ 	(476) 	(6) 	(156) 	(16) 	2,727
Selling, marketing and admin expenses 	2,723 	(3) 	2,720
Research and development expense 	739 	(36) 	(19) 	684
Other segment items 	(11) 	(19) 	(22) 	(85) 	(4) 	(141)
Adjusted Income Before Tax by Segment 	1,059 	476 	19 	28 	277 	4 	38 	- 	- 	1,901
Expenses not allocated to segments
Third Quarter
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Third Quarter
Sept 29, 2024
Non-GAAP
Cost of products sold 	33	$ 	33
Selling, marketing and admin expenses 	264 	264
Research and development expense 	- 	-
Other segment items 	1,906 	(2,013) 	(45) 	(152)
Adjusted Income Before Tax by Segment 	(2,203) 	- 	2,013 	- 	45 	- 	- 	- 	- 	(145)
Johnson & Johnson Consolidated
Third Quarter
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Third Quarter
Sept 29, 2024
Non-GAAP
Cost of products sold 	6,963	$ 	(1,171) 	(6) 	(156) 	(16) 	(2) 	5,612
Selling, marketing and admin expenses 	5,478 	(3) 	5,475
Research and development expense 	4,952 	(36) 	(19) 	(2) 	4,895
Other (Income) / Expense 	1,798 	(2,388) 	(136) 	37 	(689)
In-process research and development impairments 	- 	-
Interest (Income)/Expense 	(99) 	(99)
Restructuring 	41 	(41) 	-
Adjusted Income Before Tax 	3,338 	1,171 	2,388 	47 	328 	(37) 	38 	4 	- 	7,277
Provision for taxes on income 	644 	169 	527 	9 	59 	(9) 	6 	1 	(5) 	1,401
Net Earnings 	2,694 	1,002 	1,861 	38 	269 	(28) 	32 	3 	5 	5,876
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 20 of 22 --

Year to Date
Innovative Medicine
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 	11,670	$ 	(2,002) 	(24) 	9,644
Selling, marketing and admin expenses 	7,919 	7,919
Research and development expense 	8,361 	8,361
Other segment items 	(520) 	74 	(275) 	164 	(14) 	(571)
Adjusted Income Before Tax by Segment 	17,208 	2,002 	(74) 	- 	299 	(164) 	- 	14 	19,285
MedTech
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 	10,576	$ 	(1,433) 	(35) 	(52) 	9,056
Selling, marketing and admin expenses 	8,319 	8,319
Research and development expense 	2,052 	37 	2,089
Other segment items 	132 	(78) 	(267) 	(155) 	163 	(15) 	(220)
Adjusted Income Before Tax by Segment 	3,912 	1,433 	78 	302 	170 	(163) 	- 	15 	5,747
Expenses not allocated to segments
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 	42	$ 	42
Selling, marketing and admin expenses 	685 	685
Research and development expense 	- 	-
Other segment items 	(7,222) 	6,898 	(6) 	(330)
Adjusted Income Before Tax by Segment 	6,495 	- 	(6,898) 	- 	6 	- 	- 	- 	(397)
Johnson & Johnson Consolidated
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related 	Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 	22,288	$ 	(3,435) 	(35) 	(76) 	18,742
Selling, marketing and admin expenses 	16,923 	16,923
Research and development expense 	10,413 	37 	10,450
Other (Income) / Expense 	(7,692) 	6,894 	(123) 	(436) 	327 	(29) 	(1,059)
In-process research and development impairments 	- 	-
Interest (Income)/Expense 	(62) 	(62)
Restructuring 	144 	(144) 	-
Adjusted Income Before Tax 	27,615 	3,435 	(6,894) 	302 	475 	(327) 	- 	29 	24,635
Provision for taxes on income 	5,927 	603 	(1,541) 	58 	118 	(73) 	(672) 	9 	4,429
Net Earnings 	21,688 	2,832 	(5,353) 	244 	357 	(254) 	672 	20 	20,206
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 21 of 22 --

Innovative Medicine
Nine Months
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Nine Months
Sept. 29, 2024
Non-GAAP
Cost of products sold 	10,522	$ 	(2,087) 	(8) 	8,427
Selling, marketing and admin expenses 	7,594 	7,594
Research and development expense 	9,831 	(19) 	9,812
Other segment items 	(225) 	(399) 	(194) 	(100) 	(54) 	26 	(50) 	(996)
Adjusted Income Before Tax by Segment 	14,910 	2,087 	399 	194 	100 	54 	(26) 	- 	77 	- 	17,795
MedTech
Nine Months
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Nine Months
Sept. 29, 2024
Non-GAAP
Cost of products sold 	9,749	$ 	(1,268) 	(15) 	(206) 	(66) 	8,194
Selling, marketing and admin expenses 	7,976 	(12) 	7,964
Research and development expense 	2,103 	(69) 	(79) 	1,955
Other segment items 	173 	(15) 	(92) 	(472) 	(48) 	(454)
Adjusted Income Before Tax by Segment 	3,668 	1,268 	15 	- 	107 	747 	48 	157 	- 	- 	6,010
Expenses not allocated to segments
Nine Months
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Nine Months
Sept. 29, 2024
Non-GAAP
Cost of products sold 	72	$ 	72
Selling, marketing and admin expenses 	846 	846
Research and development expense 	- 	-
Other segment items 	4,860 	(5,052) 	(127) 	(352) 	(671)
Adjusted Income Before Tax by Segment 	(5,778) 	- 	5,052 	- 	- 	127 	352 	- 	- 	- 	(247)
Johnson & Johnson Consolidated
Nine Months
Sept 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Nine Months
Sept. 29, 2024
Non-GAAP
Cost of products sold 	20,343	$ 	(3,355) 	(15) 	(206) 	(66) 	(8) 	16,693
Selling, marketing and admin expenses 	16,416 	(12) 	16,404
Research and development expense 	11,934 	(69) 	(79) 	(19) 	11,767
Other (Income) / Expense 	4,855 	(5,466) 	(653) 	(374) 	(50) 	(1,688)
In-process research and development impairments 	194 	(194) 	-
Interest (Income)/Expense 	(433) 	(433)
Restructuring 	192 	(192) 	-
Adjusted Income Before Tax 	12,800 	3,355 	5,466 	194 	207 	928 	374 	157 	77 	- 	23,558
Provision for taxes on income 	2,165 	473 	1,224 	43 	42 	222 	5 	29 	17 	42 	4,262
Net Earnings 	10,635 	2,882 	4,242 	151 	165 	706 	369 	128 	60 	(42) 	19,296
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 22 of 22 --